TG-101348 Mechanisms: JAK2 inhibitor
- Known as:
- TG-101348 Mechanisms: JAK2 suppressor
- Catalog number:
- A-1140
- Product Quantity:
- 5mg
- Category:
- -
- Supplier:
- Activ
- Gene target:
- TG-101348 Mechanisms: JAK2 inhibitor
Related genes to: TG-101348 Mechanisms: JAK2 inhibitor
- Gene:
- JAK2 NIH gene
- Name:
- Janus kinase 2
- Previous symbol:
- -
- Synonyms:
- JTK10
- Chromosome:
- 9p24.1
- Locus Type:
- gene with protein product
- Date approved:
- 1992-04-16
- Date modifiied:
- 2019-04-23
Related products to: TG-101348 Mechanisms: JAK2 inhibitor
Related articles to: TG-101348 Mechanisms: JAK2 inhibitor
- Sleep deprivation (SD) impairs cognitive function and induces hippocampal injury, yet the gut-derived mechanisms underlying these deficits remain incompletely understood. - Source: PubMed
Publication date: 2026/08/19
Jiang ZhiqiangZhang ZhuohanShi MengqiLi XiaopingZhang XuefeiLiu ChangWang YuhaoZhu JinGu ChunyanYang Zhan - Exosomes derived from mesenchymal stem cells (MSCs) and their cargo contribute to the protective properties of MSCs in spinal cord injury (SCI). This study aimed to explore the role of Proteasome 26S subunit non-ATPase 1 (PSMD1), delivered via exosomes derived from dental pulp mesenchymal stem cells (DPMSCs-Exo), in SCI repair. - Source: PubMed
Xing XiaohuiHao YuanZhang GuanghuiXing XiaoyangJia HongfeiLiu ChenlongWang XinLi TaoLi XueyuanXiao Yilei - Tumor immune evasion is a pivotal mechanism driving therapeutic resistance and poor prognosis in lung cancer. The interleukin-20 receptor β subunit (IL20RB) is implicated in chronic inflammation and oncogenesis, but its precise function and molecular basis in non-small cell lung cancer (NSCLC) require elucidation. - Source: PubMed
Publication date: 2026/08/31
Wang YanghaoLi GuoyuWang WeizhouZhang HengruiZhang YuDeng YajieMu SirongYuan SiyuTu YulinNi JiayiHe YongwenBian Li - Breast cancer is the most frequently diagnosed malignancy among women globally and the resistance to chemotherapy and targeted therapies remains a major hindrance to successful treatment. Emerging data suggests that microRNAs (miRNAs) play a critical role in controlling drug response by modulating cellular processes such as apoptosis, drug efflux, epithelial-mesenchymal transition (EMT), cancer stem cell (CSC) maintenance and survival signaling pathways. This narrative review aims to summaries the existing data about the involvement of three important miRNAs, miR-125b, miR-375 and miR-451 in breast cancer chemoresistance, based on the studies gathered from PubMed, Scopus and Web of Science up to December 2025. Current data indicates that miR-125b has a context-dependent dual role, mainly operating as a tumor suppressor during early carcinogenesis, but contributing to acquired chemoresistance under therapeutic pressure via regulating apoptosis-related genes and CSC-associated pathways. In contrast, the biological roles of miR-375 and miR-451 are highly dependent on breast cancer subtype. miR-375 is constitutively enriched in ER-positive luminal breast cancer, where its downregulation contributes to endocrine and anti-HER2 therapy resistance via dysregulation of the IGF1R, YAP1, JAK2/STAT3 and MTDH pathways, whereas its role in triple-negative breast cancer remains incompletely understood and may involve extracellular communication within the tumor microenvironment. Similarly, lower miR-451 expression induces MDR1/P-glycoprotein, Bcl-2 and YWHAZ signaling-mediated multidrug resistance, with differences in tissue and circulation levels underscoring the relevance of extracellular vesicle trafficking and preanalytical variables including hemolysis. These data collectively suggest the potential value of these miRNAs as biomarkers and therapeutic targets but also highlight the need for subtype-specific interpretation, standardized analytical methods, and further prospective clinical validation before clinical implementation. - Source: PubMed
Publication date: 2026/09/02
Ahdi DanialRashtchi SaminHashemi SolmazKhaniani Mahmoud ShekariDerakhshan Sima Mansoori - Budd-Chiari syndrome (BCS) presents diagnostic and treatment challenges owing to its insidious onset. Genetic variants associated with BCS vary geographically; in Asian populations, the condition is primarily caused by membranous obstruction composed of endothelial cells (ECs). A better understanding of the genetic pathogenesis of membranous BCS may offer new insights into disease mechanisms. - Source: PubMed
Publication date: 2026/04/28
Gan HairunLi JiaZheng XiaodiHu XinyanYan LeyeLi BingLi LutingZhou BinZu MaohengZhao NiHe JiananWang HuijieTan MeihuaLi WeiZhou SiZhang JiangguoLi ShuaiXu SihuZhao LijianQi XiaolongZhang JingXu HaoPang Pengfei